25 XP   0   0   10

Foghorn Therapeutics Inc
Buy, Hold or Sell?

Let's analyse Foghorn Therapeutics Inc together

PenkeI guess you are interested in Foghorn Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Foghorn Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Foghorn Therapeutics Inc

I send you an email if I find something interesting about Foghorn Therapeutics Inc.

Quick analysis of Foghorn Therapeutics Inc (30 sec.)










What can you expect buying and holding a share of Foghorn Therapeutics Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$-1.81
Expected worth in 1 year
$-3.63
How sure are you?
17.6%

+ What do you gain per year?

Total Gains per Share
$-1.82
Return On Investment
-34.3%

For what price can you sell your share?

Current Price per Share
$5.30
Expected price per share
$2.7 - $8.095
How sure are you?
50%

1. Valuation of Foghorn Therapeutics Inc (5 min.)




Live pricePrice per Share (EOD)

$5.30

Intrinsic Value Per Share

$-9.17 - $-11.12

Total Value Per Share

$-10.99 - $-12.93

2. Growth of Foghorn Therapeutics Inc (5 min.)




Is Foghorn Therapeutics Inc growing?

Current yearPrevious yearGrowGrow %
How rich?-$77.1m$36.1m-$88.2m-169.3%

How much money is Foghorn Therapeutics Inc making?

Current yearPrevious yearGrowGrow %
Making money-$24.6m-$27.2m$2.6m10.6%
Net Profit Margin-400.2%-599.3%--

How much money comes from the company's main activities?

3. Financial Health of Foghorn Therapeutics Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#996 / 1016

Most Revenue
#314 / 1016

Most Profit
#743 / 1016

Most Efficient
#722 / 1016

What can you expect buying and holding a share of Foghorn Therapeutics Inc? (5 min.)

Welcome investor! Foghorn Therapeutics Inc's management wants to use your money to grow the business. In return you get a share of Foghorn Therapeutics Inc.

What can you expect buying and holding a share of Foghorn Therapeutics Inc?

First you should know what it really means to hold a share of Foghorn Therapeutics Inc. And how you can make/lose money.

Speculation

The Price per Share of Foghorn Therapeutics Inc is $5.3. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Foghorn Therapeutics Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Foghorn Therapeutics Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $-1.81. Based on the TTM, the Book Value Change Per Share is $-0.45 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.57 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Foghorn Therapeutics Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.57-10.7%-0.58-10.9%-0.64-12.1%-0.54-10.2%-0.54-10.2%
Usd Book Value Change Per Share-0.47-8.8%-0.45-8.6%-0.57-10.7%-0.11-2.0%-0.11-2.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.47-8.8%-0.45-8.6%-0.57-10.7%-0.11-2.0%-0.11-2.0%
Usd Price Per Share6.45-6.17-10.95-8.79-8.79-
Price to Earnings Ratio-2.85--2.82--4.30--3.76--3.76-
Price-to-Total Gains Ratio-13.86--15.78--19.19--11.49--11.49-
Price to Book Ratio-3.56--6.02-615.21-145.23-145.23-
Price-to-Total Gains Ratio-13.86--15.78--19.19--11.49--11.49-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share5.3
Number of shares188
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.45-0.11
Usd Total Gains Per Share-0.45-0.11
Gains per Quarter (188 shares)-85.35-20.05
Gains per Year (188 shares)-341.42-80.22
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-341-3510-80-90
20-683-6920-160-170
30-1024-10330-241-250
40-1366-13740-321-330
50-1707-17150-401-410
60-2049-20560-481-490
70-2390-23970-562-570
80-2731-27380-642-650
90-3073-30790-722-730
100-3414-34200-802-810

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.017.00.00.0%0.017.00.00.0%0.017.00.00.0%
Book Value Change Per Share0.04.00.00.0%1.011.00.08.3%3.013.01.017.6%3.013.01.017.6%3.013.01.017.6%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.017.00.0%0.00.017.00.0%0.00.017.00.0%
Total Gains per Share0.04.00.00.0%1.011.00.08.3%3.013.01.017.6%3.013.01.017.6%3.013.01.017.6%

Fundamentals of Foghorn Therapeutics Inc

About Foghorn Therapeutics Inc

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Fundamental data was last updated by Penke on 2024-04-11 07:53:02.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just not able to pay all its debts by selling its assets.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Foghorn Therapeutics Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Foghorn Therapeutics Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Foghorn Therapeutics Inc to the Biotechnology industry mean.
  • A Net Profit Margin of -417.9% means that $-4.18 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Foghorn Therapeutics Inc:

  • The MRQ is -417.9%. The company is making a huge loss. -2
  • The TTM is -400.2%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-417.9%TTM-400.2%-17.6%
TTM-400.2%YOY-599.3%+199.1%
TTM-400.2%5Y-4,133.4%+3,733.2%
5Y-4,133.4%10Y-4,133.4%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-417.9%-199.6%-218.3%
TTM-400.2%-213.0%-187.2%
YOY-599.3%-279.3%-320.0%
5Y-4,133.4%-438.4%-3,695.0%
10Y-4,133.4%-605.5%-3,527.9%
1.1.2. Return on Assets

Shows how efficient Foghorn Therapeutics Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Foghorn Therapeutics Inc to the Biotechnology industry mean.
  • -8.4% Return on Assets means that Foghorn Therapeutics Inc generated $-0.08 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Foghorn Therapeutics Inc:

  • The MRQ is -8.4%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -7.5%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-8.4%TTM-7.5%-1.0%
TTM-7.5%YOY-6.2%-1.3%
TTM-7.5%5Y-12.8%+5.3%
5Y-12.8%10Y-12.8%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-8.4%-13.5%+5.1%
TTM-7.5%-12.9%+5.4%
YOY-6.2%-11.8%+5.6%
5Y-12.8%-14.1%+1.3%
10Y-12.8%-16.0%+3.2%
1.1.3. Return on Equity

Shows how efficient Foghorn Therapeutics Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Foghorn Therapeutics Inc to the Biotechnology industry mean.
  • 0.0% Return on Equity means Foghorn Therapeutics Inc generated $0.00 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Foghorn Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-7,665.2%+7,665.2%
TTM-5Y-1,802.6%+1,802.6%
5Y-1,802.6%10Y-1,802.6%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--16.9%+16.9%
TTM--16.1%+16.1%
YOY-7,665.2%-15.1%-7,650.1%
5Y-1,802.6%-19.9%-1,782.7%
10Y-1,802.6%-20.9%-1,781.7%

1.2. Operating Efficiency of Foghorn Therapeutics Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Foghorn Therapeutics Inc is operating .

  • Measures how much profit Foghorn Therapeutics Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Foghorn Therapeutics Inc to the Biotechnology industry mean.
  • An Operating Margin of -441.3% means the company generated $-4.41  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Foghorn Therapeutics Inc:

  • The MRQ is -441.3%. The company is operating very inefficient. -2
  • The TTM is -438.8%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-441.3%TTM-438.8%-2.5%
TTM-438.8%YOY-636.9%+198.1%
TTM-438.8%5Y-5,101.5%+4,662.7%
5Y-5,101.5%10Y-5,101.5%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-441.3%-295.1%-146.2%
TTM-438.8%-225.8%-213.0%
YOY-636.9%-288.4%-348.5%
5Y-5,101.5%-477.4%-4,624.1%
10Y-5,101.5%-625.6%-4,475.9%
1.2.2. Operating Ratio

Measures how efficient Foghorn Therapeutics Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 5.41 means that the operating costs are $5.41 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Foghorn Therapeutics Inc:

  • The MRQ is 5.413. The company is inefficient in keeping operating costs low. -1
  • The TTM is 5.554. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ5.413TTM5.554-0.141
TTM5.554YOY7.520-1.967
TTM5.5545Y46.332-40.778
5Y46.33210Y46.3320.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.4133.090+2.323
TTM5.5543.264+2.290
YOY7.5203.783+3.737
5Y46.3325.679+40.653
10Y46.3327.894+38.438

1.3. Liquidity of Foghorn Therapeutics Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Foghorn Therapeutics Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 4.11 means the company has $4.11 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Foghorn Therapeutics Inc:

  • The MRQ is 4.110. The company is very able to pay all its short-term debts. +2
  • The TTM is 3.824. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ4.110TTM3.824+0.286
TTM3.824YOY6.280-2.456
TTM3.8245Y5.602-1.778
5Y5.60210Y5.6020.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.1103.914+0.196
TTM3.8244.220-0.396
YOY6.2805.388+0.892
5Y5.6026.045-0.443
10Y5.6026.406-0.804
1.3.2. Quick Ratio

Measures if Foghorn Therapeutics Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Foghorn Therapeutics Inc to the Biotechnology industry mean.
  • A Quick Ratio of 6.64 means the company can pay off $6.64 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Foghorn Therapeutics Inc:

  • The MRQ is 6.636. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 6.513. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ6.636TTM6.513+0.123
TTM6.513YOY10.565-4.052
TTM6.5135Y7.960-1.447
5Y7.96010Y7.9600.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.6363.572+3.064
TTM6.5133.998+2.515
YOY10.5655.390+5.175
5Y7.9605.969+1.991
10Y7.9606.287+1.673

1.4. Solvency of Foghorn Therapeutics Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Foghorn Therapeutics Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Foghorn Therapeutics Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 1.27 means that Foghorn Therapeutics Inc assets are financed with 127.0% credit (debt) and the remaining percentage (100% - 127.0%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Foghorn Therapeutics Inc:

  • The MRQ is 1.270. The company is unable to pay all its debts by selling its assets. -2
  • The TTM is 1.166. The company is just not able to pay all its debts by selling its assets. -1
Trends
Current periodCompared to+/- 
MRQ1.270TTM1.166+0.104
TTM1.166YOY0.923+0.243
TTM1.1665Y1.397-0.230
5Y1.39710Y1.3970.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.2700.336+0.934
TTM1.1660.334+0.832
YOY0.9230.269+0.654
5Y1.3970.366+1.031
10Y1.3970.390+1.007
1.4.2. Debt to Equity Ratio

Measures if Foghorn Therapeutics Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Foghorn Therapeutics Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Foghorn Therapeutics Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY911.301-911.301
TTM-5Y215.157-215.157
5Y215.15710Y215.1570.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.382-0.382
TTM-0.396-0.396
YOY911.3010.335+910.966
5Y215.1570.434+214.723
10Y215.1570.465+214.692

2. Market Valuation of Foghorn Therapeutics Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Foghorn Therapeutics Inc generates.

  • Above 15 is considered overpriced but always compare Foghorn Therapeutics Inc to the Biotechnology industry mean.
  • A PE ratio of -2.85 means the investor is paying $-2.85 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Foghorn Therapeutics Inc:

  • The EOD is -2.340. Based on the earnings, the company is expensive. -2
  • The MRQ is -2.847. Based on the earnings, the company is expensive. -2
  • The TTM is -2.815. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.340MRQ-2.847+0.508
MRQ-2.847TTM-2.815-0.032
TTM-2.815YOY-4.304+1.488
TTM-2.8155Y-3.760+0.944
5Y-3.76010Y-3.7600.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.340-2.259-0.081
MRQ-2.847-2.569-0.278
TTM-2.815-2.664-0.151
YOY-4.304-4.120-0.184
5Y-3.760-6.258+2.498
10Y-3.760-6.171+2.411
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Foghorn Therapeutics Inc:

  • The EOD is -2.045. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -2.489. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -2.202. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.045MRQ-2.489+0.444
MRQ-2.489TTM-2.202-0.287
TTM-2.202YOY-2.787+0.585
TTM-2.2025Y-1.751-0.451
5Y-1.75110Y-1.7510.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.045-2.924+0.879
MRQ-2.489-3.246+0.757
TTM-2.202-3.488+1.286
YOY-2.787-5.620+2.833
5Y-1.751-8.315+6.564
10Y-1.751-8.826+7.075
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Foghorn Therapeutics Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of -3.56 means the investor is paying $-3.56 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Foghorn Therapeutics Inc:

  • The EOD is -2.923. Based on the equity, the company is expensive. -2
  • The MRQ is -3.557. Based on the equity, the company is expensive. -2
  • The TTM is -6.018. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.923MRQ-3.557+0.634
MRQ-3.557TTM-6.018+2.461
TTM-6.018YOY615.215-621.233
TTM-6.0185Y145.230-151.247
5Y145.23010Y145.2300.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.9231.851-4.774
MRQ-3.5572.090-5.647
TTM-6.0182.095-8.113
YOY615.2152.844+612.371
5Y145.2303.466+141.764
10Y145.2303.815+141.415
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Foghorn Therapeutics Inc.

3.1. Institutions holding Foghorn Therapeutics Inc

Institutions are holding 61.848% of the shares of Foghorn Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-09-30Flagship Ventures Management, Inc.29.77534.59981267412000
2023-12-31FMR Inc6.60150.00142810009-88210-3.0436
2023-12-31Raymond James & Associates4.85930.01206838764216145.0252
2023-12-31Euclidean Capital LLC3.69721.14241573761-1573761-50
2023-12-31BlackRock Inc3.06790.00021305868-85890-6.1713
2023-12-31Vanguard Group Inc2.40830.0001102511364340.6316
2023-09-30Deerfield Management Co1.82660.085777752500
2023-12-31Artal Group S A1.69320.1546720720-1000000-58.1152
2023-12-31Alphabet Inc1.17680.149850090100
2023-12-31Geode Capital Management, LLC1.05330.0003448350222685.2262
2023-12-31State Street Corporation0.99290.0001422630-11240-2.5906
2023-12-31Driehaus Capital Management LLC0.80750.026734372000
2023-12-31Birchview Capital, LP0.7541.62293209305608721.1775
2023-09-30Point72 Asset Management, L.P.0.66920.004228485557002.0419
2023-12-31Northern Trust Corp0.46820.0002199274-2037-1.0119
2023-12-31Sio Capital Management, LLC0.28580.17871216721216720
2023-12-31Morgan Stanley - Brokerage Accounts0.24690.00011051133286645.4912
2023-12-31Panagora Asset Management Inc0.22790.00359701762441180.5906
2023-12-31Bank of New York Mellon Corp0.13440.000157198-13534-19.1342
2023-12-31Charles Schwab Investment Management Inc0.13020.00015544200
Total 60.87647.980925912605-1825043-7.0%

3.2. Funds holding Foghorn Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Fidelity Growth Compy Commingled Pl O3.02480.0127128753300
2024-02-29Fidelity Growth Company Fund2.1860.012193050700
2024-02-29Vanguard Total Stock Mkt Idx Inv1.40240.000359695000
2024-03-28iShares Russell 2000 ETF1.16520.00514959602400.0484
2024-02-29Fidelity Growth Company K60.6820.012229029800
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr0.67250.0022286260203737.6623
2024-01-31Fidelity Small Cap Index0.48080.002620467554762.749
2024-02-29Fidelity Series Growth Company0.43250.009184083-217-0.1177
2024-03-28iShares Russell 2000 Growth ETF0.42720.0105181861-211-0.1159
2024-02-29State St Russell Sm/Mid Cp® Indx NL Cl C0.28990.002312339317001.397
2024-02-29Fidelity Extended Market Index0.2660.0023113220-549-0.4826
2024-03-31State St Russell Sm Cap® Indx SL Cl I0.1760.00527489900
2024-02-29Vanguard Russell 2000 ETF0.17090.00597274656968.4952
2024-02-29Vanguard Health Care ETF0.14580.0023620613200.5183
2023-12-31NT R2000 Growth Index Fund - NL0.14330.01066098600
2023-12-31NT R2000 Index Fund - NL0.13740.0052584921000.1713
2024-03-28Invesco Russell 2000® Dynamic Mltfct ETF0.11690.08744976700
2024-02-29Fidelity Total Market Index0.11630.00044949500
2024-02-29Schwab Small Cap Index0.10920.00614646800
2023-12-31NT R2000 Growth Index Fund - L0.10850.01074619821794.9501
Total 12.25360.20515215852+35107+0.7%

3.3. Insider Transactions

Insiders are holding 24.794% of the shares of Foghorn Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-08-16Samuel AgrestaSELL3112978.25

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Foghorn Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.465-0.454-2%-0.568+22%-0.107-77%-0.107-77%
Book Value Per Share---1.813-1.225-32%0.848-314%0.274-762%0.274-762%
Current Ratio--4.1103.824+7%6.280-35%5.602-27%5.602-27%
Debt To Asset Ratio--1.2701.166+9%0.923+38%1.397-9%1.397-9%
Debt To Equity Ratio----0%911.301-100%215.157-100%215.157-100%
Dividend Per Share----0%-0%-0%-0%
Eps---0.566-0.578+2%-0.639+13%-0.540-5%-0.540-5%
Free Cash Flow Per Share---0.648-0.701+8%1.130-157%-0.057-91%-0.057-91%
Free Cash Flow To Equity Per Share---0.644-0.690+7%1.140-156%0.291-321%0.291-321%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---11.119--------
Intrinsic Value_10Y_min---9.172--------
Intrinsic Value_1Y_max---0.031--------
Intrinsic Value_1Y_min---0.029--------
Intrinsic Value_3Y_max---0.918--------
Intrinsic Value_3Y_min---0.860--------
Intrinsic Value_5Y_max---2.801--------
Intrinsic Value_5Y_min---2.529--------
Market Cap225599270.000-22%274550055.000262738017.750+4%465990190.250-41%374079144.706-27%374079144.706-27%
Net Profit Margin---4.179-4.002-4%-5.993+43%-41.334+889%-41.334+889%
Operating Margin---4.413-4.388-1%-6.369+44%-51.015+1056%-51.015+1056%
Operating Ratio--5.4135.554-3%7.520-28%46.332-88%46.332-88%
Pb Ratio-2.923+18%-3.557-6.018+69%615.215-101%145.230-102%145.230-102%
Pe Ratio-2.340+18%-2.847-2.815-1%-4.304+51%-3.760+32%-3.760+32%
Price Per Share5.300-22%6.4506.173+4%10.948-41%8.788-27%8.788-27%
Price To Free Cash Flow Ratio-2.045+18%-2.489-2.202-12%-2.787+12%-1.751-30%-1.751-30%
Price To Total Gains Ratio-11.393+18%-13.865-15.782+14%-19.187+38%-11.493-17%-11.493-17%
Quick Ratio--6.6366.513+2%10.565-37%7.960-17%7.960-17%
Return On Assets---0.084-0.075-11%-0.062-27%-0.128+52%-0.128+52%
Return On Equity----0%-76.6520%-18.0260%-18.0260%
Total Gains Per Share---0.465-0.454-2%-0.568+22%-0.107-77%-0.107-77%
Usd Book Value---77190000.000-52128500.000-32%36117000.000-314%11653294.118-762%11653294.118-762%
Usd Book Value Change Per Share---0.465-0.454-2%-0.568+22%-0.107-77%-0.107-77%
Usd Book Value Per Share---1.813-1.225-32%0.848-314%0.274-762%0.274-762%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.566-0.578+2%-0.639+13%-0.540-5%-0.540-5%
Usd Free Cash Flow---27578000.000-29832500.000+8%48100500.000-157%-2427764.706-91%-2427764.706-91%
Usd Free Cash Flow Per Share---0.648-0.701+8%1.130-157%-0.057-91%-0.057-91%
Usd Free Cash Flow To Equity Per Share---0.644-0.690+7%1.140-156%0.291-321%0.291-321%
Usd Market Cap225599270.000-22%274550055.000262738017.750+4%465990190.250-41%374079144.706-27%374079144.706-27%
Usd Price Per Share5.300-22%6.4506.173+4%10.948-41%8.788-27%8.788-27%
Usd Profit---24106000.000-24606500.000+2%-27218436.250+13%-10125181.824-58%-10125181.824-58%
Usd Revenue--5769000.0008538750.000-32%4807000.000+20%3243058.824+78%3243058.824+78%
Usd Total Gains Per Share---0.465-0.454-2%-0.568+22%-0.107-77%-0.107-77%
 EOD+2 -6MRQTTM+17 -14YOY+15 -175Y+10 -2210Y+10 -22

4.2. Fundamental Score

Let's check the fundamental score of Foghorn Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-2.340
Price to Book Ratio (EOD)Between0-1-2.923
Net Profit Margin (MRQ)Greater than0-4.179
Operating Margin (MRQ)Greater than0-4.413
Quick Ratio (MRQ)Greater than16.636
Current Ratio (MRQ)Greater than14.110
Debt to Asset Ratio (MRQ)Less than11.270
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-0.084
Total3/10 (30.0%)

4.3. Technical Score

Let's check the technical score of Foghorn Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5036.424
Ma 20Greater thanMa 506.661
Ma 50Greater thanMa 1006.584
Ma 100Greater thanMa 2005.689
OpenGreater thanClose5.480
Total3/5 (60.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets285,916
Total Liabilities363,106
Total Stockholder Equity-77,190
 As reported
Total Liabilities 363,106
Total Stockholder Equity+ -77,190
Total Assets = 285,916

Assets

Total Assets285,916
Total Current Assets240,181
Long-term Assets45,735
Total Current Assets
Cash And Cash Equivalents 80,336
Short-term Investments 153,721
Other Current Assets 6,124
Total Current Assets  (as reported)240,181
Total Current Assets  (calculated)240,181
+/-0
Long-term Assets
Property Plant Equipment 42,912
Long-term Assets Other 1,115
Long-term Assets  (as reported)45,735
Long-term Assets  (calculated)44,027
+/- 1,708

Liabilities & Shareholders' Equity

Total Current Liabilities58,436
Long-term Liabilities304,670
Total Stockholder Equity-77,190
Total Current Liabilities
Short-term Debt 8,518
Accounts payable 6,260
Other Current Liabilities 9,108
Total Current Liabilities  (as reported)58,436
Total Current Liabilities  (calculated)23,886
+/- 34,550
Long-term Liabilities
Capital Lease Obligations 45,073
Long-term Liabilities  (as reported)304,670
Long-term Liabilities  (calculated)45,073
+/- 259,597
Total Stockholder Equity
Common Stock4
Retained Earnings -471,564
Accumulated Other Comprehensive Income -826
Other Stockholders Equity 395,196
Total Stockholder Equity (as reported)-77,190
Total Stockholder Equity (calculated)-77,190
+/-0
Other
Capital Stock4
Cash and Short Term Investments 234,057
Common Stock Shares Outstanding 42,282
Current Deferred Revenue34,550
Liabilities and Stockholders Equity 285,916
Net Debt -35,263
Net Invested Capital -77,190
Net Working Capital 181,745
Property Plant and Equipment Gross 54,929
Short Long Term Debt Total 45,073



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-06-302018-03-312017-12-31
> Total Assets 
0
0
0
0
0
0
0
22,342
0
94,314
142,428
255,594
229,886
208,526
186,069
519,774
488,305
456,900
433,932
404,883
372,883
339,576
313,423
285,916
285,916313,423339,576372,883404,883433,932456,900488,305519,774186,069208,526229,886255,594142,42894,314022,3420000000
   > Total Current Assets 
0
0
0
0
0
0
16,885
16,885
38,967
38,967
77,764
190,687
165,315
144,672
123,953
459,562
429,824
400,066
377,760
345,798
315,970
290,492
265,442
240,181
240,181265,442290,492315,970345,798377,760400,066429,824459,562123,953144,672165,315190,68777,76438,96738,96716,88516,885000000
       Cash And Cash Equivalents 
0
0
0
0
0
0
0
14,981
0
36,563
74,620
92,795
66,449
125,166
57,841
101,136
213,645
61,206
87,604
345,798
50,641
57,703
70,306
80,336
80,33670,30657,70350,641345,79887,60461,206213,645101,13657,841125,16666,44992,79574,62036,563014,9810000000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
92,975
94,468
16,107
63,001
53,153
211,093
333,523
285,894
293,584
265,329
226,608
189,582
153,721
153,721189,582226,608265,329293,584285,894333,523211,09353,15363,00116,10794,46892,97500000000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
842
0
0
0
300,000
0
2,400
0
2,379
0
0
0
0
00002,37902,4000300,00000084200000000000
       Other Current Assets 
0
0
0
0
0
0
541
1,363
541
1,863
2,603
4,917
4,398
3,399
3,111
5,273
5,086
5,337
4,262
5,601
4,729
6,181
5,554
6,124
6,1245,5546,1814,7295,6014,2625,3375,0865,2733,1113,3994,3984,9172,6031,8635411,363541000000
   > Long-term Assets 
0
0
0
0
0
0
0
5,457
0
55,347
64,664
64,907
64,571
63,854
62,116
60,212
58,481
56,834
56,172
59,085
56,913
49,084
47,981
45,735
45,73547,98149,08456,91359,08556,17256,83458,48160,21262,11663,85464,57164,90764,66455,34705,4570000000
       Property Plant Equipment 
0
0
0
0
0
0
3,713
3,713
53,537
53,537
60,750
62,332
61,235
59,676
57,952
56,079
54,345
52,724
52,096
49,397
48,112
46,203
45,144
42,912
42,91245,14446,20348,11249,39752,09652,72454,34556,07957,95259,67661,23562,33260,75053,53753,5373,7133,713000000
       Other Assets 
0
0
0
0
0
0
1,744
1,744
1,810
1,810
3,914
2,575
3,336
4,178
4,164
4,133
4,136
4,110
4,076
4,087
4,072
2,881
0
0
002,8814,0724,0874,0764,1104,1364,1334,1644,1783,3362,5753,9141,8101,8101,7441,744000000
> Total Liabilities 
0
0
0
0
0
0
0
110,358
0
76,201
275,751
109,407
104,722
104,336
105,087
422,903
415,904
409,268
409,609
404,771
397,469
388,926
370,811
363,106
363,106370,811388,926397,469404,771409,609409,268415,904422,903105,087104,336104,722109,407275,75176,2010110,3580000000
   > Total Current Liabilities 
0
0
0
0
0
0
12,652
12,652
15,865
15,865
21,301
18,846
16,332
16,414
19,296
48,692
48,243
47,965
55,210
336,820
331,511
56,637
52,012
58,436
58,43652,01256,637331,511336,82055,21047,96548,24348,69219,29616,41416,33218,84621,30115,86515,86512,65212,652000000
       Short-term Debt 
0
0
0
0
0
0
0
5,512
0
5,368
6,081
3,981
5,888
6,946
6,991
6,994
6,103
5,669
6,670
5,970
6,346
7,670
8,372
8,518
8,5188,3727,6706,3465,9706,6705,6696,1036,9946,9916,9465,8883,9816,0815,36805,5120000000
       Short Long Term Debt 
0
0
0
0
0
0
0
4,152
0
4,988
5,990
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000005,9904,98804,1520000000
       Accounts payable 
0
0
0
0
0
0
3,439
3,439
2,981
2,981
3,554
3,680
2,911
3,406
3,821
3,819
5,071
3,635
5,257
5,414
7,288
6,933
6,496
6,260
6,2606,4966,9337,2885,4145,2573,6355,0713,8193,8213,4062,9113,6803,5542,9812,9813,4393,439000000
       Other Current Liabilities 
0
0
0
0
0
0
0
450
0
391
9,970
9,161
5,126
5,152
7,206
9,562
7,010
8,096
10,122
-11,384
-13,634
8,138
8,799
9,108
9,1088,7998,138-13,634-11,38410,1228,0967,0109,5627,2065,1525,1269,1619,97039104500000000
   > Long-term Liabilities 
0
0
0
0
0
0
0
97,706
0
60,336
254,450
90,561
88,390
87,922
85,791
374,211
367,661
361,303
354,399
67,951
65,958
332,289
318,799
304,670
304,670318,799332,28965,95867,951354,399361,303367,661374,21185,79187,92288,39090,561254,45060,336097,7060000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
19,739
19,826
19,914
0
0
0
0
0
0
0
0
0
00000000019,91419,82619,739000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
13,125
12,546
11,878
13,095
12,857
322,873
317,184
312,160
307,900
304,029
298,180
292,016
0
0
00292,016298,180304,029307,900312,160317,184322,87312,85713,09511,87812,54613,1250000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
75
75
1,970
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000001,970757500000000
> Total Stockholder Equity
0
0
0
0
0
0
0
-88,016
0
18,113
-133,323
146,187
125,164
104,190
80,982
96,871
72,401
47,632
24,323
112
-24,586
-49,350
-57,388
-77,190
-77,190-57,388-49,350-24,58611224,32347,63272,40196,87180,982104,190125,164146,187-133,32318,1130-88,0160000000
   Common Stock
0
0
0
0
0
0
1
1
1
2
1
4
4
4
4
4
4
4
4
4
4
4
4
4
444444444444412111000000
   Retained Earnings Total Equity00-433,113-403,626-373,138-344,252-318,483-291,170-264,256-235,113-209,033-185,922-162,93600000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
0
-1,292
0
0
-114
-7
6
-10
-13
-10
-1,194
-3,189
-4,864
-3,986
-2,870
-2,719
-1,893
-826
-826-1,893-2,719-2,870-3,986-4,864-3,189-1,194-10-13-106-7-11400-1,2920000000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
309,126
311,076
313,229
316,104
361,133
364,761
369,300
373,435
377,232
381,906
386,478
0
0
00386,478381,906377,232373,435369,300364,761361,133316,104313,229311,076309,12600000000000
   Treasury Stock000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
6,120
0
141,922
8,854
146,190
311,076
313,229
316,104
361,133
364,761
369,300
373,435
377,232
381,906
386,478
391,959
395,196
395,196391,959386,478381,906377,232373,435369,300364,761361,133316,104313,229311,076146,1908,854141,92206,1200000000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue34,155
Cost of Revenue-8,661
Gross Profit25,49425,494
 
Operating Income (+$)
Gross Profit25,494
Operating Expense-133,400
Operating Income-107,906-107,906
 
Operating Expense (+$)
Research Development106,238
Selling General Administrative32,372
Selling And Marketing Expenses5,210
Operating Expense133,400143,820
 
Net Interest Income (+$)
Interest Income10,591
Interest Expense-0
Other Finance Cost-0
Net Interest Income10,591
 
Pretax Income (+$)
Operating Income-107,906
Net Interest Income10,591
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-94,200-121,612
EBIT - interestExpense = -107,906
-94,200
-98,426
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-107,906-94,200
Earnings Before Interest and Taxes (EBITDA)-99,245
 
After tax Income (+$)
Income Before Tax-94,200
Tax Provision-4,226
Net Income From Continuing Ops-103,206-98,426
Net Income-98,426
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses142,061
Total Other Income/Expenses Net13,706-10,591
 

Technical Analysis of Foghorn Therapeutics Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Foghorn Therapeutics Inc. The general trend of Foghorn Therapeutics Inc is NEUTRAL with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Foghorn Therapeutics Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (0.0%) Bearish trend (0.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Foghorn Therapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 5.7817 < 8.05 < 8.095.

The bearish price targets are: 2.7.

Tweet this
Foghorn Therapeutics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Foghorn Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 7/14.
The longshort score for the Moving Averages is 0/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Foghorn Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Foghorn Therapeutics Inc. The current macd is -0.14179138.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Foghorn Therapeutics Inc price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Foghorn Therapeutics Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Foghorn Therapeutics Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Foghorn Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartFoghorn Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Foghorn Therapeutics Inc. The current adx is 18.09.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Foghorn Therapeutics Inc shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Foghorn Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Foghorn Therapeutics Inc. The current sar is 7.61333396.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Foghorn Therapeutics Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Foghorn Therapeutics Inc. The current rsi is 36.42. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Foghorn Therapeutics Inc Daily Relative Strength Index (RSI) ChartFoghorn Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Foghorn Therapeutics Inc. The current phase is Oversold in neutral market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Foghorn Therapeutics Inc price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Foghorn Therapeutics Inc Daily Stochastic Oscillator ChartFoghorn Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Foghorn Therapeutics Inc. The current cci is -147.55191316.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Foghorn Therapeutics Inc Daily Commodity Channel Index (CCI) ChartFoghorn Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Foghorn Therapeutics Inc. The current cmo is -41.8046557.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Foghorn Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartFoghorn Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Foghorn Therapeutics Inc. The current willr is -94.50171821.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Foghorn Therapeutics Inc Daily Williams %R ChartFoghorn Therapeutics Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Foghorn Therapeutics Inc.

Foghorn Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Foghorn Therapeutics Inc. The current atr is 0.72120679.

Foghorn Therapeutics Inc Daily Average True Range (ATR) ChartFoghorn Therapeutics Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Foghorn Therapeutics Inc. The current obv is 2,051,683.

Foghorn Therapeutics Inc Daily On-Balance Volume (OBV) ChartFoghorn Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Foghorn Therapeutics Inc. The current mfi is 43.94.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Foghorn Therapeutics Inc Daily Money Flow Index (MFI) ChartFoghorn Therapeutics Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Foghorn Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-30STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-01WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-04CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-05STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-07STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-08STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-11RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-14WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-26STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-28STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-29RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-02SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-04CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-09STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-10DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-01-11WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-16STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-17MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-18STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-26STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-29RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-01MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-06MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-07SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-09CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-13STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-16RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-02-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-27RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-02-28CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-04SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-05CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-06MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-12STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-14STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-15CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-20CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-21SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-03-22CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-25STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-28CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-01CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-02MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-08STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-04-09WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-11STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-16DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-17DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-04-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-04-19STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Foghorn Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Foghorn Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5036.424
Ma 20Greater thanMa 506.661
Ma 50Greater thanMa 1006.584
Ma 100Greater thanMa 2005.689
OpenGreater thanClose5.480
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Foghorn Therapeutics Inc with someone you think should read this too:
  • Are you bullish or bearish on Foghorn Therapeutics Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Foghorn Therapeutics Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Foghorn Therapeutics Inc

I send you an email if I find something interesting about Foghorn Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Foghorn Therapeutics Inc.

Receive notifications about Foghorn Therapeutics Inc in your mailbox!